These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8289584)
21. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626 [TBL] [Abstract][Full Text] [Related]
22. Effects of lamotrigine on electrically induced afterdischarge duration in anaesthetised rat, dog, and marmoset. Wheatley PL; Miller AA Epilepsia; 1989; 30(1):34-40. PubMed ID: 2492222 [TBL] [Abstract][Full Text] [Related]
24. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. Chan P; Langston JW; Di Monte DA J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813 [TBL] [Abstract][Full Text] [Related]
25. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Leng A; Mura A; Hengerer B; Feldon J; Ferger B Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025 [TBL] [Abstract][Full Text] [Related]
26. Neurochemical and behavioral aspects of lamotrigine. Leach MJ; Baxter MG; Critchley MA Epilepsia; 1991; 32 Suppl 2():S4-8. PubMed ID: 1685439 [TBL] [Abstract][Full Text] [Related]
27. Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Luszczki JJ; Antkiewicz-Michaluk L; Raszewski G; Czuczwar SJ Epilepsy Res; 2010 May; 89(2-3):207-19. PubMed ID: 20117917 [TBL] [Abstract][Full Text] [Related]
28. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Foreman MM; Hanania T; Stratton SC; Wilcox KS; White HS; Stables JP; Eller M Pharmacol Biochem Behav; 2008 Jun; 89(4):523-34. PubMed ID: 18377968 [TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effect of riluzole in MPTP-treated mice. Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056 [TBL] [Abstract][Full Text] [Related]
30. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Sundström E; Fredriksson A; Archer T Brain Res; 1990 Oct; 528(2):181-8. PubMed ID: 2271921 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease. Kanthasamy AG; Kanthasamy A; Matsumoto RR; Vu TQ; Truong DD Brain Res; 1997 Jun; 759(1):1-8. PubMed ID: 9219856 [TBL] [Abstract][Full Text] [Related]
32. Effect of lamotrigine on Na(v)1.4 voltage-gated sodium channels. Nakatani Y; Masuko H; Amano T J Pharmacol Sci; 2013; 123(2):203-6. PubMed ID: 24096830 [TBL] [Abstract][Full Text] [Related]